PAX8 (NM_003466) Human Mass Spec Standard

CAT#: PH300651

PAX8 MS Standard C13 and N15-labeled recombinant protein (NP_003457)



  View other "PAX8" proteins (15)

Need it in bulk or customized?
Get a free quote

CNY 19,520.00


货期*
4周

规格
    • 10 ug

Product images

经常一起买 (2)
Transient overexpression lysate of paired box 8 (PAX8), transcript variant PAX8A
    • 100 ug

CNY 3,080.00


Rabbit polyclonal antibody to PAX8CC (paired box 8)
    • 100 ul

CNY 6,281.00

Specifications

Product Data
Description PAX8 MS Standard C13 and N15-labeled recombinant protein (NP_003457)
Species Human
Expression Host HEK293
Expression cDNA Clone or AA Sequence RC200651
Predicted MW 48.2 kDa
Protein Sequence
Tag C-Myc/DDK
Purity > 80% as determined by SDS-PAGE and Coomassie blue staining
Concentration >0.05 µg/µL as determined by microplate BCA method
Labeling Method Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine
Buffer 25 mM Tris-HCl, 100 mM glycine, pH 7.3
Reference Data
RefSeq NP_003457
RefSeq Size 4065
RefSeq ORF 1350
Locus ID 7849
Cytogenetics 2q14.1
Summary This gene encodes a member of the paired box (PAX) family of transcription factors. Members of this gene family typically encode proteins that contain a paired box domain, an octapeptide, and a paired-type homeodomain. This nuclear protein is involved in thyroid follicular cell development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular carcinomas and atypical follicular thyroid adenomas. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Mar 2010]
Protein Families Druggable Genome, Transcription Factors
Protein Pathways Pathways in cancer, Thyroid cancer
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...